Prostatic Specific Antigen Increased
16 drugs11,381 FAERS reportsMedDRA PT
GET
/api/v1/reaction/prostatic-specific-antigen-increasedReference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. The drugs below are ranked by how often this reaction appears on FAERS reports for each drug — high share does not mean the drug caused the reaction, and absence from this list does not mean the reaction never occurred. This is not a symptom checker.
Drugs reporting Prostatic Specific Antigen Increased (16)
Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.
- 1Nilutamide1216%
- 2Enzalutamide4,3257.5%
- 3Radium4756.8%
- 4Flutamide606.1%
- 5Cabazitaxel1975.7%
- 6Abiraterone2,0095.0%
- 7Darolutamide2214.3%
- 8Degarelix1643.2%
- 9Leuprolide2,4303.1%
- 10Apalutamide3012.7%
- 11Goserelin2782.1%
- 12Talazoparib362.1%
- 13Tetraxetan2522.0%
- 14Vipivotide Tetraxetan2522.0%
- 15Triptorelin1142.0%
- 16Lutetium2551.4%
Related reactions
Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.
- Prostate Cancer8 shared · 0.47
- Prostate Cancer Metastatic5 shared · 0.31
- Metastases To Bone7 shared · 0.27
- Hormone-refractory Prostate Cancer4 shared · 0.25
- Sars-cov-2 Test Positive3 shared · 0.18
- Hot Flush9 shared · 0.17
- Laboratory Test Abnormal3 shared · 0.13
- Syringe Issue2 shared · 0.11
- Ill-defined Disorder3 shared · 0.09
- Metastases To Liver2 shared · 0.09
Note. FAERS reports are voluntarily submitted and are NOT incidence rates, signals, or causal evidence. Counts reflect reporting volume, not how often a reaction occurs. Reference statistics only.